Page last updated: 2024-08-25

oxazolidin-2-one and ezetimibe

oxazolidin-2-one has been researched along with ezetimibe in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carreira, EM; Hauser, H; Kvaernø, L; Ritter, T; Werder, M	1
Ballantyne, CM; Catapano, AL; Norata, GD	1
Akinsanya, KO; Castro-Perez, J; Chen, Y; Daniels, E; Johns, DG; Previs, SF; Roddy, TP; Wang, SP; Zhou, H	1
Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S	1
Adam, S; Durrington, PN; Soran, H	1

Reviews

2 review(s) available for oxazolidin-2-one and ezetimibe

Article	Year
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European heart journal, 2013, Volume: 34, Issue:24 Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2013
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. Atherosclerosis, 2018, Volume: 278 Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States	2018

Article

Year

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.

European heart journal, 2013, Volume: 34, Issue:24

Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases

2013

Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.

Atherosclerosis, 2018, Volume: 278

Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States

2018

Trials

1 trial(s) available for oxazolidin-2-one and ezetimibe

Article	Year
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome	2017

Article

Year

Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3

Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome

2017

Other Studies

2 other study(ies) available for oxazolidin-2-one and ezetimibe

Article	Year
Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors. Organic & biomolecular chemistry, 2005, Oct-07, Volume: 3, Issue:19 Topics: Anticholesteremic Agents; Azetidines; beta-Lactams; Ezetimibe; Heterocyclic Compounds; Isoxazoles; Molecular Structure; Oxazolidinones; Pyrazoles; Stereoisomerism	2005
In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption. Journal of lipid research, 2013, Volume: 54, Issue:10 Topics: Amides; Animals; Anticholesteremic Agents; Area Under Curve; Azetidines; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Esters; Ezetimibe; High-Density Lipoproteins, Pre-beta; Humans; Intestinal Absorption; Male; Mesocricetus; Oxazolidinones; Sulfhydryl Compounds	2013

Article

Year

Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors.

Organic & biomolecular chemistry, 2005, Oct-07, Volume: 3, Issue:19

Topics: Anticholesteremic Agents; Azetidines; beta-Lactams; Ezetimibe; Heterocyclic Compounds; Isoxazoles; Molecular Structure; Oxazolidinones; Pyrazoles; Stereoisomerism

2005

In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.

Journal of lipid research, 2013, Volume: 54, Issue:10

Topics: Amides; Animals; Anticholesteremic Agents; Area Under Curve; Azetidines; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Esters; Ezetimibe; High-Density Lipoproteins, Pre-beta; Humans; Intestinal Absorption; Male; Mesocricetus; Oxazolidinones; Sulfhydryl Compounds

2013